NVST vs STRO · P/E 56, rev $2.51B vs rev $62.0M
Envista Holdings Corp (NVST) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Envista Holdings Corp (NVST) is a medical instruments & supplies company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported NVST revenue for 2024-12-31 was $2.51B. Net income was -$1.12B. Revenue was down 2.2% from 2023-12-31 to 2024-12-31. NVST currently screens at market cap $3.72B and trailing P/E 55.8.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
NVST currently screens at market cap $3.72B and trailing P/E 55.8. STRO currently screens at market cap $470.8M.
Not investment advice. Open the NVST and STRO stock pages for the full models.
Not investment advice.